model updat thought speak
maintain outperform rate lower target price
updat model low-qual beat detail
confer call follow convers compani
incorpor detail around lower-than-expect sale
guidanc compani face number headwind
still deliv mid-singl digit ep growth expect outlook improv
driven key pharma product current blockbust
stelara imbruvica darzalex well newer asset tremfya
erleada on-going talc litig remain overhang
continu wait consum medic devic segment deliv
growth think pharma divis abl still drive
stori defens natur stori may also find
appeal broader macro economi concern increas
catalyst import upcom catalyst pdufa date
pipelin depress drug esketamin confirm
ad like advanc date compani also host
pharma busi review may hope learn
next gener pipelin asset hope drive growth
next decad current driver xarelto imbruvica
valuat maintain outperform rate lower target price
target price blend dcf rel
valuat blue sky scenario grey sky scenario
ep estim move
pleas let us know would like updat
risk primari risk rate target price slowdown
key pharma growth driver disappoint data on-going
clinic trial signific chang drug price us
surpris verdict on-going talc litig
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi
price jan rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
imbruvica darzalex lai franchis market product
compar current base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
imbruvica darzalex lai franchis market product
compar current base case assumpt grey sky valuat
base dcf driven wacc termin valu
opportun speak member ir team follow
confer call gain addit clariti dynam around certain product
well bake expect go forward
summar compani answer question
 net price declin seen us global
 driver outlook
step chang loe impact impact continu
expect consum perform market level expect continu progress
devic pharma also well despit fx impact posit well
well
 breakdown ci hold sale
current apac sale book japan sale significantli
greater current book apac sale
 one time impact
med-tech vision inventori spine pricing-rel true-up
consum lost inventori due hurrican normal comp go
forward due tough
 break stelara strength indic indic
strong uptak crohn share gain stelara sale
crohn help overal immunolog market growth share taken
remicad taken humira lost orencia
 reason timelin cad/pad indic come sale price
declin continu
ye price declin continu donut hole pickup
expect increas share growth beyond invokana product impact
donut hole product realli initi feedback cad/pad indic
also file medic ill indic hope drive growth
 xarelto litig play role use product
increas litig cost multifactori xarelto litig
realli impact use product
 break tremfya growth flat q/q
sale predomin psoriasi gain share current share
psoriasi one time impact relat clinic trial purchas repeat
 us remicad eros
see eros still share declin driven
price ex-u inventori build partner merck come
 recent opsumit import cteph indic drug
broader actelion deal live expect sinc acquir
ye live expect us issu still consid potenti
approv eu disappoint meet fda commit
cteph indic
 one time impact growth expect
see share loss due drug safeti label updat hard say growth
expect file diabet neuropathi base credenc trial data littl bit
tougher situat overal xarelto
 sequenti run run cardiolog devic
uniqu one-tim item bigger growth expect
summari jnj result along comparison estim prior report figur
provid figur
us million unless otherwis state
sale
sale
sale
sale
compani data credit suiss estim streetaccount factset consensu
figur cs comparison guidanc
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
good sold
total expens incom
incom tax basi
ep continu op
dilut ep oper
us million unless otherwis state
prepaid expens
invest crucel
loan note payabl
accru rebat return promot
note receiv employe stock ow nership
accumul incom
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
compani mention price
